Projet CMT-DN (Horizon Europe, appel à projets 2024)
Action : Doctoral Networks
Panel : Information Science and Engineering
Statut du projet : SIGNED

The CerebroMachinesTrain Doctoral Network (CMT-DN) seeks to go beyond the state-of-the-art of drug delivery systems by focusing on tiny machines (TMs) that can be engineered as stable formulation devices capable of: i) transporting the desired amount of therapeutic substance (drug) to a target area; ii) preserving its designed function under variable physiological parameters; iii) enhancing drug bioavailability; iv) preserving the healthy environment (cells, tissues, organs) with minimal to no side effects. These TMs will require innovative engineering designs to face the complex brain environment in which they must perform as a first organ testing platform. CMT-DN aims to train and transform a young, talented generation of 14 researchers to PhD level and as future leaders in the state-of-the-art engineering of TMs and brain-on-chip devices (VRAINORG) for unravelling the mechanisms and improved treatment options underlying cerebrovascular pathologies. The engineered TMs will be designed to work and tested against VRAINORG platforms, which are 3D non-animal technologies of vascularised brain organoids (healthy and disease models) incorporated within microphysiological systems (MPs). This innovative training programme will bring together a panel of academic and industry experts in TMs biomimetic therapeutic systems and brain MPs comprising five academic and four industry partner beneficiaries, consolidated through three academic and two industry-associated partners covering nine countries across Europe and beyond, including one US associated partner. By employing these emerging non-animal technologies (i.e., vascularised brain-on-chip models), the resulting innovative therapeutic systems will benefit from facilitated clinical translation while reducing the high cost and time-consuming aspects of pre-clinical animal studies.

Mots clés : engineered drug delivery devices, microfluidics, organ on chip, cerebrovascular diseases

Participants :
- Microfluidics innovation center (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 314669.16 €
- React4life spa (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 281755.08 €
- Université de Trente (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 563510.16 €
- Basque center for macromolecular design and engineering polymat fundazioa (Espagne) — Partner, beneficiary, Recherche, subvention : 564376.32 €
- Université nationale d'Irlande à Galway (Irlande) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 1364348.16 €
- Life-chip b.v. (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ibidi gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 290272.32 €
- Mimetas (Netherlands) (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 305285.76 €
- Axosim technologies llc (Etats-Unis) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Milan-Bicocca (Italie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Romanian Academy (Roumanie) — Partner, beneficiary, Recherche, subvention : 246242.52 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, associated partner, Recherche, subvention : 0.0 €
- Université du Pays basque (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de technologie de Darmstadt (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 290272.32 €